We are excited to announce The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to make EVUSHELD available during the COVID-19 pandemic
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to make EVUSHELD available during the COVID-19 pandemic and we are very fortunate to have this available to our patient population at our sites
What is COVID-19?
COVID-19 is caused by a virus called a coronavirus. You can get COVID-19 through close contact with another person who has the virus. COVID-19 illnesses have ranged from very mild (including some with no reported symptoms) to severe, including illness resulting in death. While information so far suggests that most COVID-19 illness is mild, serious illness can happen and may cause some of your other medical conditions to become worse. Older people and people of all ages with severe, long-lasting (chronic) medical conditions like heart disease, lung disease, and diabetes, immunocompromised diseases, for example, seem to be at higher risk of being hospitalized for COVID-19.
EVUSHELD (tixagevimab co-packaged with cilgavimab) is an investigational medicine used in adults and adolescents (12 years of age and older who weigh at least 88 pounds [40 kg]) for preexposure prophylaxis for prevention of COVID-19 in persons who are:
- not currently infected with SARS-CoV-2 and who have not had recent known close contact with someone who is infected with SARS-CoV-2 and
- have moderate to severe immune compromise due to a medical condition or have received immunosuppressive medicines or treatments and may not mount an adequate immune response to COVID-19 vaccination or
- For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (such as severe allergic reaction) to a COVID-19 vaccine(s) or COVID-19 vaccine ingredient(s).
The FDA has authorized the emergency use of EVUSHELD for pre-exposure prophylaxis for prevention of COVID-19 under an Emergency Use Authorization (EUA).
How will I receive EVUSHELD
- EVUSHELD consists of two investigational medicines, tixagevimab and cilgavimab.
- You will receive 1 dose of EVUSHELD, consisting of 2 separate injections (tixagevimab and cilgavimab).
- EVUSHELD will be given to you by your healthcare provider as 2 intramuscular injections, given one after the other.
Talk to your healthcare provider about receiving additional doses of EVUSHELD for ongoing protection and for further instructions.
You can keep up-to date with the latest information by visiting http://www.evusheld.com
To schedule an appointment, contact one of our Alliance locations.